Oncocyte Corporation (OCX) — Q1 2024 Form 10-Q
Entity note: The supplied filing is for Oncocyte Corporation, not “Insight Molecular Diagnostics Inc.” The reporting period is the three months ended March 31, 2024; amounts below are in U.S. dollars unless noted.
Business context and reporting period
Oncocyte is a precision-diagnostics company developing and commercializing VitaGraft transplant-monitoring tests, DetermaIO immunotherapy-response testing, and DetermaCNI cancer-treatment monitoring. VitaGraft Kidney became commercially orderable in January 2024 after a positive MolDx coverage decision. DetermaIO was available for research use and biopharma development; management aimed to complete development and make it available for clinical use later in 2024. The former DetermaRx business was divested with the 2023 sale of a majority interest in Razor and is presented as discontinued operations.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $176,000 | $297,000 |
| Gross profit (loss) | ($98,000) | $10,000 |
| Operating expenses (credits) | $9.169 million | ($5.840 million) |
| Operating income (loss) | ($9.267 million) | $5.850 million |
| Net income (loss) | ($9.129 million) | $3.033 million |
| Net cash used in operating activities | $3.830 million | $8.300 million |
- Revenue fell 41% year over year. Pharma Services revenue declined 48% to $154,000, principally because fewer customer contracts were performed; laboratory-developed test services contributed $22,000.
- Gross margin was negative in Q1 2024: costs of revenue were $252,000, plus $22,000 of acquired-intangible amortization, against $176,000 of revenue.
- Research and development expense was $2.169 million, sales and marketing $846,000, and general and administrative expense $2.673 million.
- Cash and cash equivalents were $5.578 million at March 31, 2024, down from $9.432 million at December 31, 2023. Restricted cash of $1.700 million was pledged for a lease letter of credit; cash, cash equivalents and restricted cash totaled $7.278 million.
- Total assets were $70.973 million and total liabilities $54.053 million. The filing reports no conventional borrowings at quarter-end; liabilities included $43.212 million of contingent consideration and operating lease liabilities. Shareholders’ equity was $11.588 million. Accumulated deficit was $299.005 million.
- Net operating cash use improved by $4.470 million year over year, but cash declined by $3.854 million during the quarter. Investing cash use was $24,000; there was no financing cash flow in Q1 2024.
Material changes versus the prior comparable period
- The company swung from Q1 2023 operating income of $5.850 million to an operating loss of $9.267 million. A key driver was the contingent-consideration fair-value result: a $3.312 million loss in Q1 2024 versus an $18.307 million gain in Q1 2023.
- General and administrative costs decreased 22% to $2.673 million, while sales and marketing rose 22% and R&D rose 2%.
- Q1 2023 included a $4.950 million impairment of acquired in-process R&D and a $1.283 million impairment of assets held for sale; Q1 2024 had no in-process R&D impairment and a $169,000 held-for-sale impairment.
- Q1 2023 included a $2.926 million loss from discontinued operations related to Razor; none was reported in Q1 2024.
Outlook, risks, contingencies and subsequent events
- Going concern: Management stated that continuing operating losses, negative operating cash flows and the need for additional funding raise substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance. Management planned further financing and reduced spending if needed, but judged that successful funding or sufficient cost reductions were less than probable under its assessment. The statements were prepared on a going-concern basis.
- Subsequent financing: On April 15, 2024, the company closed a private placement with gross proceeds of approximately $15.8 million. It reported approximately $9.9 million of net proceeds after offering expenses and redemption of the remaining Series A preferred stock for about $5.4 million. The offering included 5,076,900 common shares and pre-funded warrants for 342,888 shares. The filing does not provide a post-financing cash balance or updated runway.
- Bio-Rad collaboration: An April 5, 2024 agreement provides for collaboration on research-use and in-vitro diagnostic kitted transplant products. Bio-Rad may have an option for exclusive worldwide promotion and sale of certain IVD kits, subject to conditions. The agreement includes single-digit royalties on specified net sales; Bio-Rad also participated in the subsequent private placement.
- Contingencies: Contingent-consideration liabilities increased to $43.212 million from $39.900 million at year-end, driven mainly by a $3.372 million increase associated with Chronix. Valuations rely on significant unobservable assumptions, and changes could materially affect reported results. The company also reported $2.314 million of accrued acquisition-related severance and $3.233 million of operating lease liabilities.
- Commercial and regulatory risks: Revenue remains small and concentrated: two Pharma Services customers generated 62% and 26% of Q1 revenue. Reimbursement timing and rates, test development and commercialization, access to capital, and potential FDA oversight of laboratory-developed tests are material uncertainties. The filing describes the FDA’s final LDT rule, published May 6, 2024, as introducing a phased transition to greater oversight, subject to possible litigation and implementation uncertainty.
- Management gave no numerical revenue, earnings, cash-flow or other financial guidance. It expected continued operating losses and investment in product development and commercialization. The company reported no material pending litigation and stated that disclosure controls and procedures were effective.
Key facts for investors to verify
- Whether the April financing, preferred-stock redemption and subsequent spending provide adequate liquidity, given the explicit going-concern warning and no disclosed post-financing cash balance.
- Progress, clinical-use availability and reimbursement for DetermaIO, and commercial uptake and payer coverage for VitaGraft Kidney.
- Bio-Rad collaboration milestones, product responsibilities, royalty terms and the conditions governing its IVD-kit option.
- The sustainability of Pharma Services revenue, customer concentration and the assumptions behind the $43.212 million contingent-consideration valuation.
- The impact and timing of FDA LDT requirements on the company’s tests, commercialization plans and compliance costs.